The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2012
Filed:
Apr. 20, 2007
Richard Heidebrecht, Brookline, MA (US);
Joey Methot, Westwood, MA (US);
Dawn Mampreian, Boston, MA (US);
Thomas Miller, Brookline, MA (US);
Phieng Siliphaivanh, Newton, MA (US);
Richard Heidebrecht, Brookline, MA (US);
Joey Methot, Westwood, MA (US);
Dawn Mampreian, Boston, MA (US);
Thomas Miller, Brookline, MA (US);
Phieng Siliphaivanh, Newton, MA (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.